A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Pharmacyclics LLC.25 enrolled

Overview

The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Multiple Myeloma

Interventions

Motexafin Gadolinium InjectionDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Relapsed or Refractory Multiple Myeloma * ≥ 18 years old * Able to provide consent for participation * ECOG status 0-2 Lab values: * ANC ≥ 1,000/µL * WBC count ≥ 2.0/µL * Hemoglobin ≥ 8.0 g/dL * Platelet count ≥ 50,000/µL * AST and ALT ≤ 2 x ULN * Total Bilirubin ≤ 2 x ULN * Creatinine ≤ 2.0 mg/dL and * Not pregnant or lactating

Locations (1)

Robert H. Lurie Comprehensive Cancer Center

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Rate of complete response, partial response and stable disease (clinical benefit rate)

Secondary Outcomes

Progression-free survival

Safety and tolerability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.